Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17824967 | 0.84 | TP53 (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL15338114 | 0.75 | MEN1 (0.33) | ALDH1A1CYP1A2 | |
| SCHEMBL15318947 | 0.69 | SLC6A3 (0.36) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL7538968 | 0.69 | ALDH1A1 (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL26696056 | 0.68 | ALDH1A1 (0.46) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL12806717 | 0.68 | — | — | |
| SCHEMBL20303395 | 0.67 | MAPT (0.34) | ALDH1A1 | |
| SCHEMBL26923771 | 0.67 | SMN1; SMN2 (0.36) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL18255538 | 0.67 | TP53 (0.43) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL289402 | 0.66 | CYP1A2 (0.31) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931337-B1 | PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2013-10-23 | — | — | EP | disclosed |
| US-7709481-B2 | Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-05-04 | — | — | US | disclosed |
| US-7709481-B2 | Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-05-04 | — | — | US | disclosed |
| US-7709481-B2 | Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-05-04 | — | — | US | disclosed |
| US-20080261979-A1 | Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| US-20080261979-A1 | Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| US-20080261979-A1 | Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| CN-101272784-A | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI AVENTIS (FR) | 2008-09-24 | — | — | CN | disclosed |
| EP-1931337-A2 | PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007039177-A2 | PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261979-A1 | Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals | PPARD, PPARA, PPARG | KDM4E 2087/4885USP2 3985/4885ALDH1A1 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.